Dicerna Pharmaceuticals Inc (DRNA) Posts Earnings Results, Misses Expectations By $0.03 EPS

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Monday. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.08 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 1.5755% during midday trading on Friday, reaching $3.2301. 30,162 shares of the company’s stock were exchanged. The company’s market cap is $67.17 million. The firm has a 50-day moving average price of $3.19 and a 200 day moving average price of $3.02. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $6.10.

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of Dicerna Pharmaceuticals by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,978 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 2,705 shares during the period. Geode Capital Management LLC raised its position in shares of Dicerna Pharmaceuticals by 0.5% in the first quarter. Geode Capital Management LLC now owns 85,950 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 444 shares during the period. Paloma Partners Management Co raised its position in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 53,131 shares during the period. Sabby Management LLC raised its position in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 100,000 shares during the period. Finally, UBS Group AG raised its position in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the last quarter. Institutional investors and hedge funds own 58.56% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/05/19/dicerna-pharmaceuticals-inc-drna-posts-quarterly-earnings-results-misses-expectations-by-0-03-eps-updated.html.

DRNA has been the topic of several analyst reports. Leerink Swann initiated coverage on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 31st. They set a “market perform” rating and a $4.00 price target on the stock. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Monday, February 6th. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target (down from $8.00) on shares of Dicerna Pharmaceuticals in a report on Sunday, April 2nd. HC Wainwright lowered their price target on shares of Dicerna Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, April 10th. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $5.88.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply